2843 E. Grand River Avenue – #230 East Lansing, MI 48823 annie@nlmsf.org 303-783-0924

Cancer Cell Line Project

The Cancer Cell Line Project  –  Patients contributing their tissue samples during a biopsy or surgery are directly impacting LMS Research in a big way –   see the details of this program by visiting:  leiomyosarcoma.info

RCRF  Cancer Cell Line project partnership with the NLMSF established to include leiomyosarcoma ANNOUNCED APRIL 9, 2017:

The NLMSF encourages participation in this patient-driven project.
THE RARE CANCER RESEARCH FOUNDATION AND THE NLMSF HAVE PARTNERED TO INCLUDE LMS AS ONE OF THE RARE CANCERS REPRESENTED IN THIS PILOT PROGRAM:
The Cancer Cell Line project is an opportunity for patients to contribute to research in a big way – a personal way.

THE TAPUR STUDY  (www.tapur.org):

The Targeted Agent and Profiling Utilization Registry (TAPUR) study is a clinical trial for people with advanced cancer whose cancer is no longer responding to standard treatment or for whom there is no standard treatment available.
A patient’s cancer must also have a potentially actionable genomic variant already identified through a genomic test  –talk to your oncologist about this for more information about participating in a TAPUR study and the genomic testing step.
The TAPUR study aims to:
  • learn whether approved drugs might work against different cancers
  • find out how genomic or molecular tests are used to care for people with advanced cancer
  •  use the study results to help inform future studies and aid in the care of people with cancer
  • provide patients with access to therapies which may benefit them

The TAPUR STUDY website will have information about the eligibility of the study;  latest news and study announcements, the list of drugs available in the study, and a current listing of study sites in the country.